Table 2.

Baseline patient characteristics.

Baseline Characteristic, N=144	n (%) unless stated.
Male	113 (79.0)
Age, median (range)	57 (29–72)
Age <60	85 (59.4)
HCT-CI, median (range)	2 (0–8).
HCT-CI ≥3	67 (46.9)
Karnofsky performance status, median (range)	90 (60–100)
Fludarabine-refractory	60 (42.0)
Complex karyotype, n=133	16 (11.2)
FISH, n=100
del(13q)	16 (11.2)
Negative	30 (21.0)
Trisomy 12	10 (7.0)
del(11q)	14 (9.8)
del(17p)	30 (21.0)
Median number of prior therapies (range)	3 (1–10)
Refractory to most recent prior therapy	65 (45.5)
Bulky lymphadenopathy (≥5cm), n=142	24 (16.8)
Baseline β2-microglobulin, g/L, median (range)	3.1 (1.4–13.2)
Baseline β2-microglobulin ≥4.0g/L, n=137	32 (22.4)
Baseline hemoglobin (g/dl)	11.6 (6.2–16.2)
Albumin (g/l)	42 (27–51)
Most recent prior therapy:
Alemtuzumab-based treatment	26 (18)
Moderate-intensity chemoimmunotherapy	46 (32)
High-intensity chemoimmunotherapy	56 (39)
Targeted therapy/other	3 (2)
Chemotherapy alone	3 (2)
Monoclonal antibody alone	9 (6)

Abbreviations: FISH; fluorescent in situ hybridization HCT-CI; hematopoietic cell transplant comorbidity index.